drugset / Trial / NCT07748208
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.
Timeline
- Start
- 2026-10-30
- Primary completion
- 2029-06-15
- Completion
- 2029-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | — | Intramuscular |
| Subject | Inavolisib | Small molecule | — | Oral |
| Subject | Palbociclib | Small molecule | — | Oral |